European non-interventional post-authorization safety study (PASS) to evaluate cardiovascular (CV) events and all-cause mortality in patients newly exposed to abaloparatide or teriparatide First published 12/06/2025 Last updated 30/10/2026 EU PAS number:EUPAS1000000613 Study Planned